Lufepirsen clinical trials
Also written Nexagon®.
How each study uses lufepirsen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lufepirsen studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Brand
- Nexagon®
- 5
Studies by the year they started
6 studies that test it; most in 2009 (3)
| Year | Studies |
|---|---|
| 2009 | 3 |
| 2011 | 1 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
OcuNexus Therapeutics, Inc. (3) · Glaukos Corporation (2) · University of California, San Francisco (1)
Studies
Open first, then newest update. How each study uses lufepirsen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCEDRecruitingPhase 2Glaukos CorporationNCT05966493Written as lufepirsen high dose
- NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular InjuriesTerminatedPhase 2Glaukos CorporationNCT04081103Written as Nexagon® (lufepirsen) High Dose Concentration
- Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial DefectsTerminatedPhase 2University of California, San FranciscoNCT01165450Written as Nexagon
- A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)CompletedPhase 2OcuNexus Therapeutics, Inc.NCT00820196Written as Nexagon®
- The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot UlcersTerminatedPhase 1/2OcuNexus Therapeutics, Inc.NCT00820703Written as Nexagon®
- A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial DefectsWithdrawnPhase 2OcuNexus Therapeutics, Inc.NCT00821561Written as Nexagon®
Codes
What other systems call lufepirsen · ClinicalTrials.gg INT017482
- UNII (FDA) OKA0O253JZLUFEPIRSENOne source FDA
- NCI Thesaurus C184818LufepirsenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OKA0O253JZ | LUFEPIRSEN | One source FDA |
| NCI Thesaurus | C184818 | Lufepirsen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.